CSF1R inhibition with PLX5622 affects multiple immune cell compartments and induces tissue-specific metabolic effects in lean mice.
Colony stimulating factor 1 (CSF1)
Eosinophils
IL-1β
Innate lymphoid cells
Insulin secretion
Insulin sensitivity
Macrophages
PLX5622
Journal
Diabetologia
ISSN: 1432-0428
Titre abrégé: Diabetologia
Pays: Germany
ID NLM: 0006777
Informations de publication
Date de publication:
12 2023
12 2023
Historique:
received:
25
05
2023
accepted:
07
07
2023
medline:
7
11
2023
pubmed:
4
10
2023
entrez:
4
10
2023
Statut:
ppublish
Résumé
Colony stimulating factor 1 (CSF1) promotes the proliferation, differentiation and survival of macrophages, which have been implicated in both beneficial and detrimental effects on glucose metabolism. However, the physiological role of CSF1 signalling in glucose homeostasis and the potential therapeutic implications of modulating this pathway are not known. We aimed to study the composition of tissue macrophages (and other immune cells) following CSF1 receptor (CSF1R) inhibition and elucidate the metabolic consequences of CSF1R inhibition. We assessed immune cell populations in various organs by flow cytometry, and tissue-specific metabolic effects by hyperinsulinaemic-euglycaemic clamps and insulin secretion assays in mice fed a chow diet containing PLX5622 (a CSF1R inhibitor) or a control diet. CSF1R inhibition depleted macrophages in multiple tissues while simultaneously increasing eosinophils and group 2 innate lymphoid cells. These immunological changes were consistent across different organs and were sex independent and reversible after cessation of the PLX5622. CSF1R inhibition improved hepatic insulin sensitivity but concomitantly impaired insulin secretion. In healthy islets, we found a high frequency of IL-1β Macrophages and macrophage-derived factors, such as IL-1β, play an important role in physiological insulin secretion. A better understanding of the tissue-specific effects of CSF1R inhibition on immune cells and glucose homeostasis is crucial for the development of targeted immune-modulatory treatments in metabolic disease. The RNA-Seq dataset is available in the Gene Expression Omnibus (GEO) under the accession number GSE189434 ( http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE189434 ).
Identifiants
pubmed: 37792013
doi: 10.1007/s00125-023-06007-1
pii: 10.1007/s00125-023-06007-1
pmc: PMC10627931
doi:
Substances chimiques
PLX5622
0
Glucose
IY9XDZ35W2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2292-2306Informations de copyright
© 2023. The Author(s).
Références
Nature. 2013 Oct 10;502(7470):245-8
pubmed: 24037376
Gastroenterology. 2014 Nov;147(5):1106-18.e11
pubmed: 25128759
Arch Immunol Ther Exp (Warsz). 2003;51(3):169-77
pubmed: 12894871
Cell Metab. 2019 Feb 5;29(2):457-474.e5
pubmed: 30595478
Neuron. 2014 Apr 16;82(2):380-97
pubmed: 24742461
Nat Commun. 2019 Aug 21;10(1):3758
pubmed: 31434879
Lancet. 2019 Aug 10;394(10197):478-487
pubmed: 31229240
J Leukoc Biol. 2020 Feb;107(2):205-219
pubmed: 31330095
Aging (Albany NY). 2020 Feb 2;12(3):2101-2122
pubmed: 32007953
Int J Obes (Lond). 2020 Jan;44(1):245-253
pubmed: 30926949
iScience. 2020 Jan 24;23(1):100775
pubmed: 31962237
J Immunol Methods. 2016 May;432:13-23
pubmed: 26705686
Diabetes. 2007 Sep;56(9):2356-70
pubmed: 17579207
J Clin Invest. 2003 Dec;112(12):1796-808
pubmed: 14679176
BMC Genomics. 2014 Jul 22;15:620
pubmed: 25051960
Nat Med. 2005 Feb;11(2):183-90
pubmed: 15685173
Diabetes. 2005 Aug;54(8):2351-9
pubmed: 16046301
Endocrinology. 2009 Dec;150(12):5218-29
pubmed: 19819943
J Exp Med. 2013 Dec 16;210(13):2939-50
pubmed: 24323357
Proc Natl Acad Sci U S A. 2017 Nov 28;114(48):E10418-E10427
pubmed: 29133420
Am J Pathol. 2011 Jul;179(1):240-7
pubmed: 21703406
Proc Natl Acad Sci U S A. 2020 Sep 22;117(38):23336-23338
pubmed: 32900927
Immunity. 2017 Nov 21;47(5):928-942.e7
pubmed: 29166590
J Leukoc Biol. 2004 Aug;76(2):359-67
pubmed: 15178709
J Immunother Cancer. 2017 Jul 18;5(1):53
pubmed: 28716061
Nat Immunol. 2017 Mar;18(3):283-292
pubmed: 28092375
Cell Rep. 2020 Feb 4;30(5):1627-1643.e7
pubmed: 32023474
J Clin Invest. 2003 Dec;112(12):1821-30
pubmed: 14679177
Cell Metab. 2017 Jul 5;26(1):185-197.e3
pubmed: 28683286
Proc Natl Acad Sci U S A. 1987 Sep;84(17):6179-83
pubmed: 2819867
Diabetologia. 2009 Aug;52(8):1686-8
pubmed: 19504085
PLoS One. 2011;6(9):e24358
pubmed: 21931688
Front Endocrinol (Lausanne). 2020 Feb 19;11:62
pubmed: 32140136
Cell. 2014 Dec 4;159(6):1312-26
pubmed: 25480296
Proc Natl Acad Sci U S A. 1990 Jun;87(12):4828-32
pubmed: 2191302
Front Immunol. 2018 Feb 07;9:191
pubmed: 29467768
Proc Natl Acad Sci U S A. 2014 Apr 1;111(13):E1211-20
pubmed: 24639504
J Immunol. 2018 Mar 15;200(6):2209-2223
pubmed: 29440354
Am J Physiol Gastrointest Liver Physiol. 2010 Jan;298(1):G107-16
pubmed: 19875703
Diabetes. 1985 Dec;34(12):1253-9
pubmed: 3905458
Development. 1994 Jun;120(6):1357-72
pubmed: 8050349
Commun Biol. 2022 Apr 19;5(1):370
pubmed: 35440795
Blood. 2010 Nov 11;116(19):3955-63
pubmed: 20682855
Blood. 2002 Jan 1;99(1):111-20
pubmed: 11756160
J Exp Med. 2015 Sep 21;212(10):1497-512
pubmed: 26347472